Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. by Huntington, S et al.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Pregnancy is associated with elevation of liver
enzymes in HIV-positive women on
antiretroviral therapy
Susie Huntington
a,b, Claire Thorne
a, Marie-Louise Newell
c,
Jane Anderson
d, Graham P. Taylor
e, Deenan Pillay
b,f, Teresa Hill
b,
Pat A. Tookey
a, Caroline Sabin
b, on behalf of the UK Collaborative HIV
Cohort (UK CHIC) Study and the UK and Ireland National Study of
HIV in Pregnancy and Childhood (NSHPC)
Objective: The objective of this study is to assess whether pregnancy is associated with
an increased risk of liver enzyme elevation (LEE) and severe LEE in HIV-positive women
on antiretroviral therapy (ART).
Design: Two observational studies: the UK Collaborative HIV Cohort (UK CHIC) study
and the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC).
Methods: Combined data from UK CHIC and NSHPC were used to identify factors
associated with LEE (grade 1–4) and severe LEE (grade 3–4). Women starting ART in
2000–2012 were included irrespective of pregnancy status. Cox proportional hazards
were used to assess ﬁxed and time-dependent covariates including pregnancy status,
CD4
þ cell count, drug regimen and hepatitis B virus/hepatitis C virus (HBV/HCV)
coinfection.
Results: One-quarter (25.7%, 982/3815) of women were pregnant during follow-up,
14.2% (n¼541) when starting ART. The rate of LEE was 14.5/100 person-years in and
6.0/100 person-years outside of pregnancy. The rate of severe LEE was 3.9/100 person-
years in and 0.6/100 person-years outside of pregnancy. The risk of LEE and severe LEE
was increased during pregnancy [LEE: adjusted hazard ratio (aHR) 1.66 (1.31–2.09);
severe LEE: aHR 3.57 (2.30–5.54)], including in secondary analyses excluding 541
women pregnant when starting ART. Other factors associated with LEE and severe LEE
included lower CD4
þ cell count (<250cells/ml), HBV/HCV coinfection and calendar
year.
Conclusion: Although few women developed severe LEE, this study provides further
evidence that pregnancy is associated with an increased risk of LEE and severe LEE,
reinforcing the need for regular monitoring of liver biomarkers during pregnancy.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Antiretroviral therapy (ART) reduces morbidity and
improvesthelifeexpectancyofpeoplelivingwithHIV.In
pregnancy, it dramatically reduces the risk of vertical
transmission of the virus [1,2]. However, all ART drugs
can cause hepatotoxicity of varying severity [3–6].
Alanine aminotransferase (ALT) is a biomarker of hepatic
function; elevated levels indicate hepatotoxicity, or other
liver dysfunction. The extent to which pregnancy affects
the risk of developing ART-induced hepatotoxicity is
unclear; although high rates of LEE have been observed
among HIV-positive pregnant women using nevirapine
(NVP) [7,8], lower rates of LEE, comparable to those
seen in nonpregnant populations, have also been reported
[9–11]. Cross-sectional studies comparing the rate of
LEE in pregnant and nonpregnant women have also
generated conﬂicting results [12–18]. In most of these
studies, women started ART during pregnancy and
follow-up ended at delivery.
We assess whether pregnancy is associated with an
increased risk of LEE and severe LEE using data from
women in the UK Collaborative HIV Cohort (UK
CHIC) Study and the UK and Ireland National Study of
HIV in Pregnancy and Childhood (NSHPC).
Materials and methods
Data collection
The UK CHIC Study is an ongoing observational study
collating data from (currently 16) UK-based HIV clinics.
Pseudonymized data from adults’ clinical records are
collected annually, including ethnicity, age, ARTuse, all
CD4
þcellcounts,viralloadsandliverfunctiontest(LFT)
results [19]. Hepatitis B virus (HBV)/hepatitis C virus
(HCV) coinfection status was determined from clinic
notes or on the basis of a positive test result for HCV
antibody or HBV surface antigen. The NSHPC is a
comprehensive observational surveillance study of HIV-
positive women accessing antenatal care in all maternity
units in the UK and Ireland. Data collected include
ethnicity, age and expected date of delivery, details of
ARTuse, CD4
þ cell counts and viral loads in pregnancy
[1]. Both studies had ethics approval. Informed consent
was not required. Record linkage between these two
studies (based on an algorithm using basic demographic
and clinical data) has been ongoing since 2010 [20].
Inclusion criteria
The analyses included women not on ART on 31
December 1999 who started ART during 2000–2012
whilst aged 16–49 years, who had more than one ALT
measurement while on ART and CD4
þ cell count and
viral load data available during follow-up. The date of
ART initiation was the baseline date and only the ﬁrst
initiation of ARTover the study period was considered
for each woman. Women with ALT more than ﬁve times
the upper limit of normal (ULN) at baseline, indicating
liver dysfunction, were excluded (n¼10). Women were
included irrespective of pregnancy status/outcome or
ARTexperience prior to 2000.
Outcomes
ALT levels were graded according to the Division of
AIDS toxicity guidelines [21]. LEE (grade 1–4) was
deﬁned as at least 1.25 ULN (assumed to be 40IU/l)
among women with no evidence of LEE at baseline or at
least 1.25 baseline ALT among women with ALT
>ULN at baseline. Severe LEE (grade 3–4) was similarly
deﬁned using more than ﬁve-fold changes. Regimen
changes (any addition or discontinuation of at least one
drug in the regimen) within 3 months of incident LEE
were examined.
It was assumed that women with no baseline ALT data
(n¼1856) had ALT ULN. A sensitivity analysis was
undertaken excluding women with no baseline ALT. As
ALT is affected by plasma volume expansion (PVE), the
upper limit of the reference range used in clinical practice
is 8IU/l lower in pregnancy than at other times (32IU/l)
[22]. In sensitivity analysis, the fall in ALT during
pregnancy was accounted for by adding 8IU/l to ALT
measurements taken during pregnancy.
As the risk of LEE may be higher in the ﬁrst few months
of ART use, an increase in the risk of LEE in pregnant
women may be a consequence of women starting ART
antenatally.Asensitivityanalysiswasthereforeundertaken
excluding women who were already pregnant when
starting ART.
Although women could act as their own controls,
contributing datawhen pregnant and when not pregnant,
somewomen did not have a pregnancy during follow-up.
It is unlikely that all differences between women with and
without a pregnancy were accounted for in adjusted
analyses. Therefore, a further sensitivity analysis was
undertaken excluding women with no pregnancy during
follow-up.
ALT monitoring was assessed by calculating the
percentage ofwomenwith atleast oneALTmeasurement
during each calendar year and the median number of
measurements among these women.
Analysis
Thebaselinecharacteristicsof womenwithand without a
pregnancy at any point during follow-up were compared
using chi-squared and Kruskal–Wallis tests. Follow-up
started on the date of ﬁrst ARTand was censored at ART
discontinuation, at last clinic visit or at 31 December
2012, whichever occurred ﬁrst. Kaplan–Meier analyses
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were used to describe the probability of LEE/severe
LEE. Cox proportional hazards models were used to
calculate crude and adjusted hazard ratios for the
associations between factors and incident LEE/severe
LEE. Fixed characteristics at baseline considered for
inclusion were the pre-ART CD4
þ cell count (not
known  250/251–350/351–500/>500cells/ml), pre-
ART viral load ( />100000copies/ml), ALTwithin the
previous 6 months, route of exposure, ethnicity and
HBV/HCV coinfection. Time-dependent covariates
considered, assessed at 1-month intervals, were age,
pregnancy status, cumulative use of ART, latest CD4
þ
cell count category, latest viral load category and current
drug regimen (dichotomised as used/not used for each
drug). Any covariates that were associated with the
outcome (P<0.10) inunivariate modelswere considered
for inclusion in multivariable models; covariates with a P
value 0.05 or lesswere retained in the ﬁnal model, aswere
age, route of exposure, ethnicity and HBV/HCV
coinfection, as these were of interest for our research
question. Analyses were performed using SAS (version
9.4, SAS Institute, Cary, North Carolina, USA).
Results
The 3815 women contributed 17753 person-years
of follow-up; median duration of follow-up was 4.1
[interquartile range (IQR) 1.6–7.2] years. When starting
ART, the median age was 34 years, 66.0% were of black-
Africanethnicity,90.6%acquiredHIVheterosexuallyand
8.3% had HBV/HCV coinfection (Table 1). Overall,
38.3% had been diagnosed with HIV within the past
3monthsand46.5%hadaCD4
þcellcountof250cells/ml
or less at ART start. At baseline, 304 women had an ALT
aboveULN,representing8.0%ofthetotalor15.5%ofthe
1959 women with a baseline ALT measurement.
Around one in seven (14.2%, n¼541) women were
already pregnant when starting ART, with around a
quarter (25.7%, n¼982) being pregnant at some time
during follow-up (742 women had one and 240 more
than one pregnancy). Women with a pregnancy during
follow-up differed from women with no pregnancy: they
were less likely to be of white ethnicity (12.7 vs. 18.6%,
P<0.001), to have acquired HIV via injecting drug use
(IDU) (0.9 vs. 4.0%, P<0.001) and be HBV/HCV
coinfected (5.7 vs. 9.2%, P<0.001). Women with a
pregnancy were less likely to start ARTwith CD4
þ cell
count 250cells/ml or less (49.6 vs. 65.7%) and were
correspondingly more likely to start with CD4
þ cell
count more than 500cells/ml (12.3 vs. 6.7%, P<0.001).
They were also less likely to have ALT above ULN at
baseline (4.2 vs. 9.3%, P<0.001). Women with a
pregnancy were more likely to use a NVP-containing
regimen during follow-up [25.3% (n¼248) vs. 17.1%
(n¼484), P<0.001]. Among women who started ART
whilst pregnant, 23.3% (n¼126) used a nonnucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen
(n¼117 NVP-containing) as part of their initial regimen
compared with 61.3% (n¼2008, n¼615 NVP-contain-
ing) of women who were not pregnant when starting
ART.
In the ﬁrst 6 months on ART, the proportion of women
with at least one ALT measurement was similar in both
groups(63.4vs.65.4%,P¼0.27)andthemediannumber
of ALT measurements was the same [2 (IQR 0–4),
P¼0.72]. The median number of ALT measurements
undertaken in the ﬁrst 6 months on ARTremained stable
over time (three or four for each year). ALT monitoring,
in general, did not increase over time.
Incidence of liver enzyme elevation
Overall, 1080 (28.3%) women developed LEE. After
1 year on treatment, the cumulative incidence of LEE
was 15% [95% conﬁdence interval (95% CI) 14–17],
increasing to 30% (95% CI 28–31) by 5 years. The overall
estimated rate of LEE was 6.3 (95% CI 5.9–6.7)/100
person-years. The rate of LEE was 14.5 (11.4–17.5)/100
person-yearsin pregnancyand6.0 (5.6–6.4)/100person-
years outside pregnancy. In women with HBV/HCV
coinfection, 149 (47%) developed LEE, with LEE rates
being 14.4 (12.1–16.7)/100 person-years in women with
HBV/HCV coinfection and 5.8 (5.4–6.1)/100 person-
years in women without coinfection.
In the ﬁrst 6 months on ART, the rate of LEE was 21.8
(19.7–23.8)/100 person-years. For this period, the rate
was higher in women whowere pregnant than in women
who were not pregnant [32.2 (23.9–40.5)/100 person-
years vs. 20.8 (18.7–22.8)/100 person-years, respect-
ively]. In women who had been on ART for more than
6 months, the rate of LEE was 4.2 (3.9–4.6)/100 person-
years. The rate was higher in women who were pregnant
than in women who were not pregnant [7.0 (4.5–9.5)/
100 vs. 4.2 (3.8–4.5)/100 person-years, respectively]
(Table 2).
LEE occurred during 11.6% (63/541) of pregnancies
during which ART was started. In women who
developed LEE during such a pregnancy, it occurred at
a median of 30(IQR 25–33) weeksgestation and 8(IQR
4–12) weeks after ART initiation. In pregnancies
conceived on ART during which LEE occurred, it
occurred at median of 16 (IQR 9–28) weeks gestation.
Incidence of severe liver enzyme elevation
Overall, 151 (4.0%) women developed severe LEE. The
cumulative incidence of severe LEE at 1 and 5 years
after treatment initiation was 2.2% (1.7–2.7%) and 4.3%
(3.5–5.0%), respectively. The overall estimated rate of
severe LEE was 0.7 (0.6–0.8)/100 person-years. The rate
of severe LEE was 3.9 (2.4–5.3)/100 person-years in
pregnancy and 0.6 (0.5–0.7)/100 person-years outside
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pregnancy. In women with HBV/HCV coinfection,
18 (5.7%) developed severe LEE; the rates were 1.2 (0.6–
1.8) in women with HBV/HCV coinfection and
0.7 (0.6–0.8)/100 person-years in women without
coinfection.
In the ﬁrst 6 months on ART, the rate of severe LEE was
2.9 (2.2–3.7)/100 person-years. For this period, the rate
was higher in women whowere pregnant than in women
whowere not pregnant [9.0 (4.7–13.3)/100 vs. 2.4 (1.7–
3.0)/100 person-years, respectively]. In women who had
been on ART for more than 6 months, the rate of severe
LEE was 0.5 (0.4–0.6)/100 person-years. The rate was
higher in women who were pregnant than in women
who were not pregnant [2.0 (0.7–3.2)/100 vs. 0.4 (0.3–
0.5)/100 person-years, respectively] (Table 2).
Severe LEE occurred during 3.3% (18/541) of pregnan-
cies during which ART was started. In women who
developed severe LEE during such a pregnancy, it
occurred at a median of 30 (IQR 27–31) weeks gestation
and 9 (IQR 3–12) weeks after ART initiation. In
pregnancies conceived on ART during which severe LEE
occurred, it occurred at a median of 24 (IQR 11–29)
weeks gestation.
Factors associated with liver enzyme elevation
Being pregnant was independently associated with an
increased risk of LEE (Table 2). This remained the case
in further analysis excluding women who were already
pregnant at ART initiation [adjusted hazard ratio (aHR)
1.91 (1.28–2.84), P¼0.001]. The latest CD4
þ cell
count, but not the CD4
þ c e l lc o u n ta tA R Ti n i t i a t i o n ,
was associated with LEE with women who attained a
CD4
þ cell count more than 500cells/mlh a v i n ga
decreased risk of LEE. Women receiving zidovudine
(ZDV)-containing regimens had a lower risk of LEE
than women not receiving ZDV. Although women
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Table 1. Characteristics of HIV-positive women at the start of antiretroviral therapy in 2000–2012 (nU3815).
Characteristic n (%)
Age, median [IQR (years)] 34 [29–39]
Exposure group Heterosexual sex 3456 (90.6)
IDU 122 (3.2)
Other/NK 237 (6.2)
Ethnicity Black-African 2517 (66.0)
White 651 (17.1)
Black-Caribbean 133 (3.5)
Other/NK 514 (13.5)
HIV-HBV/HCV coinfection 317 (8.3)
Year of starting ART 2000–2002 793 (20.8)
2003–2005 1020 (26.7)
2006–2008 1062 (27.8)
2009–2014 940 (24.6)
Time since HIV diagnosis <3 months 1460 (38.3)
3–<12 months 651 (17.1)
1–<5 years 928 (24.3)
 5 years 776 (20.3)
Median months [IQR] 7.5 [1.5–46]
CD4
þ cell count (cells/ml)  250 1774 (46.5)
251–350 564 (14.8)
351–500 319 (8.4)
>500 237 (6.2)
NK 921 (24.1)
Viral load (copies/ml)  400 463 (12.1)
400– 10000 605 (15.9)
10000– 100000 1074 (28.2)
 100000 779 (20.4)
NK 894 (23.4)
ALT above ULN 304 (8.0)
Previous ART use 218 (5.7)
Pregnancy status when starting ART Pregnant 541 (14.2)
<20 weeks gestation 208 (5.5)
 20 weeks gestation 333 (8.7)
Type of ART regimen NNRTI 2134 (55.9)
PI
a 1176 (30.8)
NRTI
b 130 (3.4)
Other 375 (9.8)
ALT, alanine aminotransferase; HBV, hepatitis B; HCV, hepatitis C; IDU, injecting drug use; IQR, interquartile range; NK, not known; NNRTI,
nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; ULN, upper limit
of normal.
aOne thousand and thirty-six women were on a ritonavir-boosted PI and 140 were on a nonboosted PI.
bThis includes 68 women on zidovudine monotherapy. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
receiving NVP or efavirenz were at an increased risk of
LEE (Table 3), this risk dropped with a longer exposure
to the NNRTI drug class. Other factors independently
associated with LEE were HBV/HCV coinfection and
having acquired HIV via IDU. There was a small, but
signiﬁcant, increase in the risk of developing LEE in
later calendar years.
Factors associated with severe liver enzyme
elevation
Factors associated with developing severe LEE were
similar to those associated with developing any LEE
(Table 4). Being pregnant was associated with an
increased risk; this was also the case when women
who started ART whilst pregnant were excluded [aHR
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Table 2. Rates of liver enzyme elevation and severe liver enzyme elevation per 100 person-years, with 95% conﬁdence intervals, according to
pregnancy status and duration on antiretroviral therapy.
All women Pregnant Not pregnant
LEE
Overall 6.3 (5.9–6.7) 14.5 (11.4–17.5) 6.0 (5.6–6.4)
 6 months on ART 21.8 (19.7–23.8) 32.2 (23.9–40.5) 20.8 (18.7–22.8)
>6 months on ART 4.2 (3.9–4.6) 7.0 (4.5–9.5) 4.2 (3.8–4.5)
Severe LEE
Overall 0.7 (0.6–0.8) 3.9 (2.4–5.3) 0.6 (0.5–0.7)
 6 months on ART 2.9 (2.2–3.7) 9.0 (4.7–13.3) 2.4 (1.7–3.0)
>6 months on ART 0.5 (0.4–0.6) 2.0 (0.7–3.2) 0.4 (0.3–0.5)
ART, antiretroviral therapy; LEE, liver enzyme elevation.
Table 3. Results from unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with the incidence of
any liver enzyme elevation.
Unadjusted Adjusted
HR (95% CI) P HR (95% CI) P
Pregnant 1.38 (1.11–1.73) 0.004 1.66 (1.31–2.09) <0.001
Age (per 10-year increase) 1.00 (0.92–1.08) 0.98 1.05 (0.96–1.14) 0.31
Route of exposure Heterosexual sex Reference <0.001 Reference 0.02
IDU 2.60 (2.00–3.37) 1.55 (1.12–2.15)
Other/NK 1.02 (0.78–1.33) 0.93 (0.71–1.22)
Ethnicity Black-African Reference 0.001 Reference 0.35
White 1.37 (1.18–1.60) 1.17 (0.98–1.38)
Black-Caribbean 1.08 (0.76–1.52) 1.03 (0.73–1.46)
Other/NK 1.09 (0.91–1.31) 1.08 (0.90–1.30)
Calendar year 1.06 (1.03–1.08) <0.001 1.05 (1.03–1.08) <0.001
HBV/HCV coinfection 2.22 (1.87–2.64) <0.001 1.85 (1.52–2.27) <0.001
LEE at baseline 1.56 (1.21–2.01) <0.001 –
Latest CD4
þ cell count (cells/ml)  250 Reference <0.001 Reference
251–350 0.85 (0.70–1.04) 0.82 (0.67–0.99) 0.05
351–500 0.88 (0.73–1.06) 0.83 (0.68–1.00) 0.05
>500 0.77 (0.63–0.93) 0.72 (0.59–0.87) 0.001
NK 0.62 (0.52–0.76) 0.62 (0.51–0.75) <0.001
CD4
þ cell count at ART start (cells/ml)  250 Reference 0.004 –
251–350 0.74 (0.57–0.96)
351–500 0.73 (0.58–0.92)
>500 0.66 (0.53–0.82)
NK 0.81 (0.65–1.01)
Latest viral load (copies/ml)  50 Reference –
>50 0.88 (0.74–1.04) 0.13
Viral load at ART start (copies/ml)  100000 Reference –
>100000 0.88 (0.70–1.10) 0.25
ART drug in regimen Zidovudine 0.68 (0.59–0.79) <0.001 0.73 (0.62–0.85) <0.001
Efavirenz 1.00 (0.88–1.14) 0.52 1.26 (1.07–1.48) 0.005
Nevirapine 1.02 (0.88–1.18) 0.77 1.54 (1.27–1.87) <0.001
Raltegravir 1.88 (1.14–3.08) 0.01 –
Duration on ART (per additional year) 1.03 (0.95–1.12) 0.43 –
Duration on PI regimen 1.07 (1.03–1.11) 0.001 –
Duration on NNRTI regimen 0.94 (0.91–0.98) 0.004 0.90 (0.86–0.95) <0.001
Duration on NRTI regimen 1.10 (0.98–1.24) 0.11
Adjusted by covariates in the table with aHR presented. ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard
ratio; IDU, injecting drug use; IQR, interquartile range; LEE, liver enzyme elevation; NK, not known; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; ULN, upper limit of normal. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
4.99 (2.55–9.80), P<0.001]. Calendar year, age and
CD4
þcellcountwereallassociatedwiththeriskofsevere
LEE, but there were no speciﬁc antiretroviral drugs that
were signiﬁcantly associated with severe LEE in
univariate analyses. There were no deaths related to
severe LEE.
Sensitivity analyses
Pregnancy remained associated with an increased risk of
LEE and severe LEE when the analysis included only
women who had a pregnancy during follow-up. The
main ﬁndings were unaltered when women with no
baseline ALT measurement were excluded and when the
fall in ALT during pregnancy (due to PVE) was
accounted for.
Treatment switches and interruptions among
women with liver enzyme elevation
Among women who developed LEE, 5.9% (64/1080)
stopped/interrupted ARTand 12.0% (n¼130) switched
regimen at a median of 44 (15–69) and 24 (9–50) days
after LEE diagnosis, respectively. The percentage who
altered their regimen was 14.8% (122/826) among
women with ALT 50–100IU/l, 21.0% (34/162) among
women with ALT 101–200IU/l and 41.3% (38/92)
among women with ALT more than 200IU/l (global
P<0.001).
Women who developed LEE in pregnancy were more
likely to stop/interrupt their regimen or switch their
regimen than women who were not pregnant when they
developed LEE [stop/interrupt regimen: 23.9% (21/88)
vs. 4.3% (43/992), respectively, odds ratio (OR) 6.92
(3.88–12.33), P<0.001; switch regimen: 21.6% (19/88)
vs. 11.2% (111/992), respectively, OR 2.19 (1.27–3.78),
P¼0.005].
Among the 21 women who developed LEE in pregnancy
and then stopped/interrupted ART, 20 stopped at
delivery or postpartum and one interrupted ART during
pregnancy. This woman conceived on an efavirenz-
containing regimen, interrupted ART in the ﬁrst
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Table 4. Results from unadjusted and adjusted Cox proportional hazards regression analyses to identify factors associated with the incidence of
severe liver enzyme elevation.
Unadjusted Adjusted
HR (95% CI) P HR (95% CI) P
Pregnant 3.68 (2.40–5.64) <0.001 3.57 (2.30–5.54) <0.001
Age (per 10-year increase) 0.74 (0.60–0.91) 0.005 0.77 (0.61–0.98) 0.04
Route of exposure Heterosexual sex Reference 0.09 Reference 0.16
IDU 1.70 (0.79–3.63) 1.16 (0.46–2.93)
Other/NK 0.37 (0.12–1.16) 0.33 (0.10–1.06)
Ethnicity Black-African Reference 0.60 Reference 0.58
White 1.26 (0.84–1.90) 1.31 (0.84–2.04)
Black-Caribbean 0.86 (0.32–2.34) 0.84 (0.31–2.28)
Other/NK 0.89 (0.53–1.48) 0.91 (0.54–1.53)
Calendar year 1.04 (0.99–1.10) 0.13 1.06 (1.00–1.12) 0.05
HBV/HCV coinfection 1.64 (1.00–2.68) 0.05 1.55 (0.88–2.73) 0.13
LEE at baseline 1.19 (0.59–2.43) 0.63 –
Latest CD4
þ cell count (cells/ml)  250 Reference 0.14 Reference
251–350 0.61 (0.34–1.09) 0.51 (0.29–0.91) 0.02
351–500 1.01 (0.63–1.62) 0.77 (0.48–1.24) 0.28
>500 0.66 (0.39–1.12) 0.30 (0.30–0.84) 0.01
NK 0.65 (0.39–1.08) 0.57 (0.35–0.95) 0.03
CD4
þ cell count at ART start (cells/ml)  250 Reference 0.97 –
251–350 1.11 (0.69–1.78)
351–500 1.19 (0.63–2.25)
>500 0.91 (0.40–2.10)
NK 1.02 (0.69–1.51)
Latest viral load (copies/ml)  50 Reference –
>50 0.94 (0.60–1.47) 0.79
Viral load at ART start (copies/ml)  100000 Reference –
>100000 1.01 (0.67–1.51) 0.96
ART drug in regimen Zidovudine 0.84 (0.59–1.20) 0.33 –
Efavirenz 0.75 (0.53–1.07) 0.12 –
Nevirapine 0.91 (0.61–1.36) 0.63 –
Raltegravir 2.42 (0.78–7.60) 0.13 –
Duration on ART (per 1-year increase) 0.92 (0.76–1.11) 0.38 –
Duration on PI regimen 1.10 (0.98–1.24) 0.10 –
Duration on NNRTI regimen 0.89 (0.80–1.00) 0.05 –
Duration on NRTI regimen 0.95 (0.69–1.31) 0.75 –
Adjusted by covariates in the table with aHR presented. ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard
ratio; IDU, injecting drug use; IQR, interquartile range; LEE, liver enzyme elevation; NK, not known; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; ULN, upper limit of normal. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
trimester and started a ZDV-containing regimen in the
second trimester. Among the 19 women who developed
LEE in pregnancy and then switched regimen, 17
switched during pregnancy, in the ﬁrst (n¼4), second
(n¼7) or third trimester (n¼6), and two switched
postpartum.
Among women who developed severe LEE, 13.3%
(20/151) stopped/interrupted ART and 25.2% (n¼38)
switched regimen within 90 days at a median of 41
(17–50) days and 23 (6–51) days, respectively, after
the elevated ALT measurement. The difference in the
percentage of women who altered their regimen, among
women who developed severe LEE in pregnancy and
women who developed severe LEE whilst not pregnant
was not statistically signiﬁcant [stop/interrupt regimen:
22.2% (6/27) vs. 11.3% (14/124), respectively, OR 2.25
(0.78–5.41); switch regimen: 25.9% (7/27) vs. 25.0%
(31/124), respectively, OR 1.05 (0.41–2.72)].
Discussion
In HIV-positive women on ART, the overall rates of LEE
and severe LEE were 6.3/100 and 0.7/100 person-years,
respectively. The rate of severe LEE was lower than in a
study of pregnant and nonpregnant women in Co ˆte
d’Ivoire who started NVP-containing regimens [2.2
(1.1–4.0)/100 person-years] [17]. Few other studies
reported LEE rates. In our study, LEE and severe LEE
developed during 11.6 and 3.3% of pregnancies during
which ART had been initiated, lower than that reported
among pregnant women starting NVP-containing regi-
mens [10,12] but similar to pregnant women starting
nelﬁnavir-containing regimens [12] or when only a small
proportion of women start NVP-containing regimens
[18].
The initial period on ART is a time of increased toxicity
risk. This was seen in our study, wherein half of the 30%
of women who developed LEE within 5 years developed
it within 1 year. Therefore, it is to be expected that some
of the women who were pregnant when starting ART
would develop LEE. However, our results suggest that
pregnancy itself confers an additional risk of 70% for LEE
and 260% for severe LEE. The increase in risk was
apparent both in women who had recently started ART
and women who had been on treatment for more than
6 months.
Some previous cross-sectional studies also adjusting
for factors associated with LEE failed to observe an
association between LEE and pregnancy [14,16,18], but
only assessed pregnancies during which ARTwas started
and had a short follow-up. In our study and in a U.S.
study [13], which also observed an association between
pregnancyand LEE, pregnancies conceived on ARTwere
included, and in our study, women acted as their own
controls by contributing data when pregnant and not
pregnant. The mechanism by which pregnancy could
increase susceptibility to ART-induced hepatotoxicity is
notclearandmaydifferbyARTdrug[23].Thebiological
mechanisms that increase susceptibility to liver dysfunc-
tion during pregnancy in other diseases, such as hepatitis
E, including those unique to pregnancy, such as obstetric
cholestasis, are diverse and poorly understood.
As ALT is a biomarker used to indicate hepatocellular
injury, LEE does not equate to ART-induced hepato-
toxicity. In pregnancy, LEE could be a result of obstetric
complications. However, the rate of LEE was higher than
would be anticipated due to obstetric complications; a
study of non-HIV-positive pregnant women observed
liver dysfunction in 3% of pregnancies [24], which is
thought to be similar in HIV-positive pregnant women
[25].
Biomarkers, including ALT, change over the course of a
pregnancy as a result of PVE [22]. In sensitivity analysis,
we took into account these changes. Although this did
not alter the main ﬁndings, ignoring changes in ALT that
occurduringnormalpregnancycouldmeanthatLEEand
severe LEE are underestimated during pregnancy.
Clinicians should be mindful that a lower ALT threshold
may be more appropriate during pregnancy. Previous
studies that did not observe an association between
pregnancy and LEE may have had a different outcome if
the ALT threshold for deﬁning LEE differed according to
pregnancy status [16–18]. Further work is needed to
examine normal changes in ALT during pregnancy
among HIV-positive women.
HBV/HCV infection can lead to LEE and is associated
with an increased risk of ART-induced hepatotoxicity
[26]. In our setting, HBV/HCV coinfection increased
the risk of LEE 1.9-fold and severe LEE 1.6-fold.
The latter association was not statistically signiﬁcant,
probably due to insufﬁcient statistical power, as few
women with HBV/HCV coinfection developed severe
LEE (n¼18).
The clinical consequences of LEE are unclear; few
women developed severe LEE (2% of pregnancies and
0.7% of women) and none had liver failure. Due to the
risk of viral rebound, treatment changes are not
recommended wherein toxicity is mild, but there is
currently no agreement on how to manage pregnant
women on ARTwho develop LEE. Close monitoring of
liver biomarkers and any symptoms of toxicity, including
rashes, are important [27]. Particularly with severe LEE,
further tests are required, as this could indicate obstetric
complications.
To minimize hepatotoxicity risk, NVP-containing regi-
mens are not recommended for individuals starting ART
Liver enzyme elevation in pregnancy Huntington et al. 807 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
with CD4
þcell countmore than250cells/ml [28]. Inour
study, wherein one-ﬁfth of women were receiving a
NVP-containing regimen, higher CD4
þ cell count
category, as a time-dependent variable, was associated
with a lower risk of LEE and severe LEE, which counters
the evidence that starting ART with CD4
þ cell count
morethan250cells/ml increasestheriskofNVP-induced
hepatotoxicity [14,29], although other studies have not
found such an association [8,16].
As anticipated, the proportion of women who altered
their ARTwas higher when LEE was more severe. It is
not surprising that women who experienced LEE in
pregnancy were more likely to stop/interrupt treatment
than women who experienced LEE outside pregnancy, as
manyof the pregnant women would have planned to stop
ART at delivery irrespective of LEE. The woman who
interrupted ART during pregnancy probably did so to
avoid using efavirenz [30]. It is of concern that pregnant
women who experienced LEE had two times the odds of
switching regimen than women who experienced it
outside pregnancy.
There was a small but statistically signiﬁcant increase in
risk of LEE and severe LEE with increasing calendar year.
This is unlikely to be due to changes in ALT monitoring,
as monitoring did not increase overall or in women
starting treatment. It could be due to changes in variables
not measured by the UK CHIC Study but known
to affect ALT such as BMI, alcohol consumption,
co-medication or use of illicit drugs [31].
There were a number of other limitations to the analysis.
Datawere obtained from an observational studyand LFTs
were not performed according to a schedule but as a part
of routine monitoring and where clinically indicated.
This means that women with a high risk of, or with
clinical indication for, hepatopathy will have had more
ALT measurements. This could increase the detection
rate of LEE in those with hepatopathy and therefore lead
to an overestimation of the LEE incidence. In addition,
HIV-positive women are more regularly monitored in
pregnancy than at other times, typically having a
minimum of three LFTs (at ﬁrst antenatal visit, 20 weeks
and 36 weeks gestation) than once every 6 months among
women stable on treatment. This could introduce bias,
increasing the detection rate of LEE in pregnancy.
However, among women starting treatment, the average
number of ALT measurements was the same in and
outside pregnancy.
This study provides further evidence that pregnancy
increases the risk of LEE among HIV-positive women
on ART, highlighting the importance of close moni-
toring of ALT in pregnancy. Further work is needed to
support or refute these ﬁndings and to provide clinicians
with clearer guidance on the management of LEE
in pregnancy.
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